AZD1222

BIOLOGICAL18 trials

Sponsors

AstraZeneca, R-Pharm, Humanity & Health Medical Group Limited, Masaryk University, Valneva Austria GmbH

Conditions

Adverse Reaction to VaccineCOVID-19COVID-19 VaccineCOVID-19, SARS-CoV-2COVID-19, Vaccine Adverse Events of Special InterestCOVID19 VaccineChronic Liver DiseaseCovid19 Vaccine

Phase 1

Study of AZD1222 for the Prevention of COVID-19 in Japan

CompletedNCT04568031

AstraZenecaCOVID-19

Start: 2020-08-23End: 2021-11-22Updated: 2024-03-01

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

CompletedNCT04684446

R-PharmCOVID-19

Start: 2021-09-15End: 2022-03-29Updated: 2022-06-03

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

CompletedNCT04760730

R-PharmCOVID-19

Start: 2021-07-13End: 2022-07-26Updated: 2022-10-26

Phase 2

Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention

CompletedNCT04686773

R-PharmCOVID-19

Start: 2021-03-05End: 2022-03-18Updated: 2022-06-03

Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults

CompletedNCT04973449

AstraZenecaCOVID-19, SARS-CoV-2

Start: 2021-06-27End: 2022-08-02Updated: 2024-09-19

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

CompletedNCT05197153

Medigen Vaccine Biologics Corp.COVID-19 Vaccine

Start: 2022-01-22End: 2022-10-28Updated: 2023-03-15

Phase 3

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

CompletedNCT04516746

AstraZenecaCOVID-19, SARS-CoV-2

Start: 2020-08-28End: 2023-02-10Updated: 2024-02-05

AZD1222 Vaccine for the Prevention of COVID-19

WithdrawnNCT04540393

AstraZenecaCOVID-19

Start: 2020-09-02End: 2022-05-11Updated: 2021-10-01

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

CompletedNCT04864561

Valneva Austria GmbHSARS-CoV-2 Virus Infection

Start: 2021-04-26End: 2023-03-13Updated: 2023-03-20

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

CompletedNCT05011526

Medigen Vaccine Biologics Corp.Covid19 Vaccine

Start: 2021-10-08End: 2022-05-21Updated: 2022-09-30

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

CompletedNCT05198596

Medigen Vaccine Biologics Corp.COVID-19 Vaccine

Start: 2022-07-30End: 2023-03-30Updated: 2023-10-23

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

CompletedNCT05426343

Medigen Vaccine Biologics Corp.COVID-19 Vaccine

Start: 2022-07-09End: 2023-01-07Updated: 2023-10-23

Phase 4

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

CompletedNCT04775069

Humanity & Health Medical Group LimitedChronic Liver Disease

Start: 2021-05-21End: 2023-09-30Updated: 2023-10-04

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

CompletedNCT04914832

Shabir MadhiCOVID-19, Pneumonia, Viral

Start: 2021-08-30End: 2022-09-30Updated: 2023-08-29

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

TerminatedNCT05057897

AstraZenecaCOVID-19, SARS-CoV-2

Start: 2022-01-31End: 2023-04-19Updated: 2025-01-27

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

CompletedNCT05343871

Albert B. Sabin Vaccine InstituteCOVID-19

Start: 2022-07-05End: 2024-01-11Updated: 2024-01-30

Unknown Phase

COVID-19 Vaccines Safety Tracking (CoVaST)

RecruitingNCT04834869

Masaryk UniversityAdverse Reaction to Vaccine, COVID19 Vaccine

Start: 2021-04-01End: 2026-12-31Target: 30000Updated: 2022-04-06

EU Secondary Data Post-Authorisation Safety Study of AZD1222

CompletedNCT05126992

AstraZenecaCOVID-19, Vaccine Adverse Events of Special Interest

Start: 2022-02-18End: 2024-01-24Updated: 2025-01-28

Related Papers

Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil

BMJ Public Health2025-07-011 citations

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials

The Journal of Infectious Diseases2024-09-037 citations

Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study

Vaccines2024-08-032 citations

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

UNC Libraries2024-06-21

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

2024-06-125 citations

Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity

Frontiers in Immunology2024-05-172 citations

Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data

Epidemics2024-04-151 citations

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.

2023-09-298 citations

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.

2023-07-038 citations

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

2023-06-235 citations

One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.

2023-06-026 citations

EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL

International Journal of Infectious Diseases2023-05-011 citations

Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.

2023-04-127 citations

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated

Frontiers in Immunology2023-01-1312 citations

AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection

Cell Reports Medicine2022-12-1522 citations

1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination

Open Forum Infectious Diseases2022-12-01

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Journal of Clinical Investigation2022-09-1431 citations

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

The Lancet Infectious Diseases2022-09-0547 citations

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.

2021-10-2226 citations

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

New England Journal of Medicine2021-09-29662 citations

2 more papers not shown